{"id":18309,"date":"2021-06-11T10:24:47","date_gmt":"2021-06-11T14:24:47","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18309"},"modified":"2021-06-11T10:24:47","modified_gmt":"2021-06-11T14:24:47","slug":"fdas-approval-of-biogens-new-alzheimers-drug-has-huge-cost-implications-for-medicare-and-beneficiaries","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18309","title":{"rendered":"FDA\u2019s Approval of Biogen\u2019s New Alzheimer\u2019s Drug Has Huge Cost Implications for Medicare and Beneficiaries"},"content":{"rendered":"

(By\u00a0Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published June 10, 2021)<\/p>\n

The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer\u2019s that afflicts millions of people has loomed large in discussions over drug prices in the U.S.\u2014and now we\u2019re about to find out. After a nearly 20-year dry spell in new treatments for Alzheimer\u2019s disease, the Food and Drug Administration (FDA) just approved a new Alzheimer\u2019s medication, Aduhelm (aducanumab), developed by Biogen, with an expected annual price tag of $56,000. While the scientific community debates the evidence of the effectiveness of this new drug, the FDA\u2019s decision raises hope for Alzheimer\u2019s patients and their families, along with serious cost concerns for patients and payers, particularly Medicare.\u00a0 Continue reading here…<\/a><\/p>\n

\"\"<\/a><\/p>\n

Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"
(By\u00a0Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published June 10, 2021) The question of what would happen when<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,6,9,15],"tags":[],"class_list":["post-18309","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-medicare-general","category-medicare-advantage","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18309"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18309\/revisions"}],"predecessor-version":[{"id":18310,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18309\/revisions\/18310"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}